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Abstract: The gene for Rhotekin 2 (RTKN2) was originally identified in a promyelocytic cell line resistant to oxysterol-induced 
apoptosis. It is differentially expressed in freshly isolated CD4+ T-cells compared with other hematopoietic cells and is down-regulated 
following activation of the T-cell receptor. However, very little is known about the function of RTKN2 other than its homology to 
Rho-GTPase effector, rhotekin, and the possibility that they may have similar roles. Here we show that stable expression of RTKN2 in 
HEK cells enhanced survival in response to intrinsic apoptotic agents; 25-hydroxy cholesterol and camptothecin, but not the extrinsic 
agent, TNFα. Inhibitors of NF-KappaB, but not MAPK, reversed the resistance and mitochondrial pro-apoptotic genes, Bax and Bim, 
were down regulated. In these cells, there was no evidence of RTKN2 binding to the GTPases, RhoA or Rac2. Consistent with the 
role of RTKN2 in HEK over-expressing cells, suppression of RTKN2 in primary human CD4+ T-cells reduced viability and increased 
sensitivity to 25-OHC. The expression of the pro-apoptotic genes, Bax and Bim were increased while BCL-2 was decreased. In both cell 
models RTKN2 played a role in the process of intrinsic apoptosis and this was dependent on either NF-KappaB signaling or expression 
of downstream BCL-2 genes. As RTKN2 is a highly expressed in CD4+ T-cells it may play a role as a key signaling switch for regulation 
of genes involved in T-cell survival.
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Background
Rhotekin 2 (RTKN2) is the recently identified member 
of the rhotekin proteins.1 The two proteins, rhotekin 
and RTKN2, have homologues in most mammals 
including human, chimpanzee, horse, mouse, dog 
and rat; and each of the proteins has an N-terminal 
Rho-GTPase binding domain (designated HR-1) and 
a mid-sequence pleckstrin homology (PH) domain.1 
Although the amino acids are only 65% homologous, 
the similar protein architecture indicates that they 
probably share functional characteristics. Rhotekin 
was discovered in 1996 in an experiment that 
identified potential RhoA binding proteins.2 Since 
then a number of interacting proteins for rhotekin 
have been described.2–8 In particular the murine 
rhotekin HR-1 domain has been shown to bind to 
Rho-GTPase (but not to Rac1 or Cdc42) and to inhibit 
GTPase-activating protein (GAP) activity.2 A number 
of studies have found that rhotekin is involved 
in functional PDZ protein complexes9 dependent on 
the C-terminal sequence QSPV-COOH8,9 present in 
both rhotekin and RTKN2. The interactions between 
rhotekin and PDZ proteins have suggested roles 
in gene expression,8 neuronal functions,4 and cell 
polarity development.5
A specific anti-apoptotic role for rhotekin 
was reported by a Taiwanese group in two 2004 
publications.10,11 Having identified rhotekin in a 
majority of gastric cancers tested, and linking it to 
metastatic progression,11 they established a stable 
rhotekin expressing gastric cell line and showed 
that the cells were able to withstand apoptosis from 
sodium butyrate and serum deprivation. Investigation 
of the anti-apoptotic signaling pathways indicated 
that NF-kappaB inhibitors (but not PI3-kinase or 
MAP kinase inhibitors) abrogated the effect.10 Also 
rhotekin over expression lead to induction of a 
number of NF-kappaB regulated anti-apoptotic genes, 
cIAP-2, BCL-xL, A1, and A20. Conversely, reducing 
rhotekin expression by siRNA greatly sensitized cells 
to apoptosis.10 It was concluded that human rhotekin 
induced cell survival and Rho mediated signaling with 
the activation of downstream antiapoptotic genes, and 
may be linked to gastric tumorigenesis.10,11
Similarly, RTKN2 was identified in cells induced to 
survive the apoptotic effects of an oxysterol, 25-OHC.12 
The oxysterols are oxygenated derivatives of cholesterol 
and have been directly associated with apoptosis in 
many cell types including hematopoietic and leukemic 
cells.13–15 However the link of RTKN2 expression to cell 
survival was by association only and information on this 
gene is currently limited to identification of a number 
of transcribed isoforms and the significant expression 
in lymphocytic tissues and cells.1 RTKN2 is highly 
expressed in organs comprising sites of lymphopoiesis; 
the thymus, spleen, bone marrow, lung and colon. 
In hematopoietic subsets from all sources, peripheral 
blood (PB), bone marrow (BM) and umbilical cord blood 
(UCB), expression was restricted to the T-lymphocytes 
and the immature B-cells derived from the bone marrow.1 
Further separation of T-cells showed that RTKN2 was 
differentially expressed in the CD4+ T-cells compared to 
the CD8+ cells. Activation of the T-cell receptor (TCR) 
in CD4+ helper T-cells using phytohemagglutinin 
(PHA) or anti-CD3 induced marked and sustained down 
regulation of RTKN2 mRNA.1 In mice thymic subsets, 
RTKN2 was approximately 10 to 14-fold higher in 
immature double negative (CD4-/CD8-) and double 
positive (CD4+/CD8+) immature populations than the 
single positive mature T-cells (unpublished data).
The gene expression suggests that RTKN2 is 
a signaling protein that may play a key role in 
lymphocyte development and survival. The aim of 
this study was to develop a stable model of RTKN2 
over expression in human embryonic kidney (HEK) 
cells (with a low endogenous expression of RTKN2) 
and investigate, 1) its role in responses to apoptotic 
agents and, 2) potential protein interactions; and then 
use gene knockdown (shRNA) in primary human 
CD4+ T-cells (with high expression levels of RTKN2), 
to assess viability and responses to apoptosis, and 
regulated gene expression.
Results
stable expression of rTKn2  
in heK Flp-in cells
Confirmation of protein expression
Stable HEK cells were established with constructs 
containing either the gene of interest, pcDNA5/FRT-
His-V5-RTKN2, or a control gene, pcDNA5/FRT/
V5-His/CAT. The control construct expressed the 
hygromycin resistance gene and chloramphenicol 
acetyltransferase, (CAT). Three days following the 
passage of cells, HEK Flp-In stable cells (two controls, 
CAT #1 and #2, and two genes of interest, RTKN2 
#1 and #2) were lysed and analysed by western blot. 
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Each of the over-expressing proteins was tagged with 
a V5 epitope and clearly visualized using an anti-V5 
antibody (Fig. 1). The HEK over expressing cell lines 
were designated CAT control cells or RTKN2 cells.
response of stable cells to apoptosis induced 
by oxysterol, camptothecin and TnFα
To determine whether over expression of RTKN2 
played a direct role in resistance to apoptosis, three 
apoptotic agents were chosen and the percentage of 
cells undergoing apoptotic cell death was measured 
by flow cytometry using Annexin-V/PI. The 
oxysterol, 25-OHC, was chosen as resistance to 
this oxysterol was previously related with elevated 
levels of RTKN21,12 and has been shown to act via 
the intrinsic pathway.16 Camptothecin is a topo-
isomerase inhibitor and acts intrinsically via DNA, 
while TNFα induces extrinsic apoptosis directly via 
the TNF death receptor. The CAT control and RTKN2 
cells were equally sensitive to the extrinsic apoptotic 
effects of TNFα at all doses (Fig. 2C), while RTKN2 
cells were significantly resistant to both the intrinsic 
agents, oxysterol (25-OHC) (P  0.0001) (Fig. 2A) 
and camptothecin (p  0.0001, main effect between 
cell lines) (Fig. 2B). Treatment with camptothecin 
failed to induce a dose response, however the results 
indicated that RTKN2 cells were significantly more 
resistant to apoptosis compared to CAT control cells 
at all doses, 10 µM (p = 0.028), 20 µM (p = 0.006) 
and 30 µM (p = 0.023) (Fig. 2B).
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Figure 1. Western blot analysis of stable cell lines to assess expression 
of rTKn2 and CAT in heK cells. Three days following the passage of 
the cells, each of the stable cell lines (CAT#1 and #2, rTKn2#1 and #2) 
was lysed for protein analysis. 20 ug of total protein from each sample 
was denatured and run under reducing conditions on a 4%–20% gradient 
sDs PAge gel, before transfer and blotting with anti-V5, and anti-mouse 
hrP. The hrP was visualized using eCL reagent and imaged using the 
UVP ChemiDoc-it imaging system (DKsh). The correct sized proteins 
(CAT, 32 kDa and rTKn2, 80 kDa) are evident in the appropriate lanes.
Pathway inhibitor treatments
To determine if the apoptotic resistance in RTKN2 
cells was mediated via activation of either NF-KappaB 
or MAPK pathways, the compounds, curcumin and 
parthenolide (both NF-KappaB inhibitors) and PD89059 
(a MAPK inhibitor) were tested in combination with 
a single dose of the oxysterol, 25-OHC (5 ug/ml). As 
demonstrated in the previous experiment, there were 
significantly less RTKN2 cells undergoing apoptosis 
in the presence of 5ug/ml 25-OHC than the CAT 
control cells (Fig. 3A and B, no inhibitors, p = 0.014), 
although due to experimental variability the overall 
degree of apoptosis was slightly higher than the 
previous experiment. When treated in combination 
with NF-KappaB pathway inhibitors, curcumin and 
parthenolide, the resistance was reversed with RTKN2 
cells becoming equally sensitive as the CAT control 
cells. In contrast PD89059, the MAPK inhibitor, did not 
alter the level of resistance of the RTKN2 cells (Fig. 3A 
and B). This was not a generalized effect of the curcumin 
and parthenolide as there would have been a comparable 
increase in apoptosis in the CAT control cells.
increased nF-kappaB activation in rTKn2 cells
The activation of NF-KappaB was measured in 
cultured stable cells three days post-passage. Both 
control and RTKN2 cells had a visible steady-state 
level of phospho NF-KappaB but the degree of 
phosphorylation was greater in the RTKN2 cells 
(Fig. 4), indicating increased NF-KappaB activation.
expression of apoptotic genes
As the RTKN2 cells were resistant to the two intrinsic 
apoptotic stimuli (that act directly via the mitochondrial 
death pathway), the expression of members of the 
BCL-2 family of genes was assessed by real time 
PCR in the stable HEK cell lines that had been 
cultured over a period of 6 days. The expression of the 
pro-apoptotic gene, Bax, was significantly lower in 
RTKN2 stables at day 0 (p = 0.01) and day 3 (p = 0.03) 
with an overall decrease of expression in RTKN2 cells 
(p  0.0001, main effect) (Fig. 5A). The expression of 
Bim (pro-apoptotic) was also overall lower in RTKN2 
cells (p  0.013, main effect) compared to the CAT 
control cells (Fig. 5B). The expression of BCL-2 was 
not significantly different between the CAT control 
cells and RTKN2 cells but did decrease over the 6 day 
culture period in both cell lines (p = 0.01) (Fig. 5C).
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Figure 2. Percentage of apoptotic heK cells following induction of apoptosis by various agents. results are expressed as mean ± seM (n = 6, 
triplicate treatments/cell line, duplicate cell lines/group). The heK stable cells were cultured for 48 h in the presence or absence of three apoptotic 
agents: intrinsic agents, 25-OhC and camptothecin, and the extrinsic agent, TnFα. An aliquot of cells were removed and stained with annexin V 
and Pi to assess the degree of apoptosis. The apoptotic and dying cells were calculated by combining both the percentage of annexin V+ve and 
Pi+ve cells in a gated population. A) The RTKN2 cells were overall significantly different to control cells (p  0.0001, general Linear Model (gLM) in 
response to 25Oh-C. At concentrations of 5 ug/ml and 10 µg/ml they were significantly more resistant than control cells (*p  0.0001, gLM). B) The 
treatment of Camptothecin failed to induce a dose response however, the results indicated that RTKN2 cells were significantly more resistant at 10 µM 
(*p = 0.028, gLM), 20 µM (*p = 0.006, gLM) and 30 µM (*p = 0.023, gLM). c) The rTKn2 expressing cells were equally sensitive to the apoptotic 
effects of TnFα.
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Figure 3. Percentage of apoptotic heK cells following induction of apoptosis by 25-OhC in combination with various pathway inhibitors. results are 
expressed as mean ± seM (n = 4, duplicate samples/cell line, duplicate cell lines/group). A) The heK stable cells were cultured for 48 h in the presence 
of the intrinsic apoptotic agent, 25-OhC, and in combination with either curcumin (10 uM), parthenolide (10 uM) (both nF-KappaB inhibitors) or PD98059 
(7.5 uM) (MAPK inhibitor). At 48 h an aliquot of cells was removed and stained with annexin V and Pi to assess the degree of apoptosis. The apoptotic 
cells were calculated by combining the percentage of annexin V+ve and Pi+ve cells in a gated population. There were significantly less RTKN2 cells 
undergoing apoptosis after treatment of 25-OHC alone or in combination with PD98059, the MAPK inhibitor (*p = 0.014); but in the presence of both 
curcumin and Parthenolide, the rTKn2 cells were as sensitive to cell death as the CAT control cells. B) The representative flow cytometry dot plots for 
each of the treatment groups in the bar graphs above. The horizontal axes correspond to the FL-1 green fluorescence channel that detected annexin 
V FITC, and the vertical axes correspond to the FL-3 red fluorescence channel that detected taining with propidium iodide (PI). The top row of dot plots 
represents the results for the CAT control cells and the bottom row represents the dot plots for the rTKn2 cells. region 3 (r3) represents the viable cells 
(annexin V–ve and Pi–ve) and region 2 (r2) represents the apoptotic dying cells (annexin V+ve and Pi+ve).
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Figure 4. Western blot analysis of phosphorylated nF-KappaB. Three days following passage of the cells CAT control and rTKn2 cells were lysed for 
protein analysis. The total protein was estimated and approximately 20 ug of each sample was denatured and run under reducing conditions on a 4%–20% 
gradient sDs PAge gel, before transfer and blotting with anti-phospho nF-KappaB, and anti-rabbit hrP, The protein loading was quantitated using 
anti-beta actin. The hrP was visualized using eCL reagent and imaged using the UVP ChemiDoc-it imaging system (DKsh). The level of phospho-nF-
KappaB was greater in the rTKn2 cells.
immunoprecipitation with rhoA and rac2
As rhotekin is a strong binding partner of the GTPase, 
RhoA, a potential interaction with RTKN2 was tested. 
The stable RTKN2 cells were transiently transfected 
with constructs expressing constitutively active RhoA 
or Rac2 (a lymphocytic GTPase). Although all the 
proteins were successfully co-expressed neither RhoA 
nor Rac2 were co-precipitated with RTKN2 (Fig. 6).
shrnA silencing of rTKn2  
in CD4+ T cells
shrnA plasmid sequences and assessment  
of rTKn2 gene knockdown
The shRNA plasmids chosen for this study coded for 
four separate RTKN2 sequences within the full coding 
region of RTKN2 (Table 1). To measure the efficiency 
of the knockdown, a U1 promoter in the vector 
construct induced green fluorescent protein (GFP) 
expression in the cells. The RTKN2 shRNA plasmids 
were designated: shRNA nonsense sequence (NC), 
RTKN2 shRNA seq 1 (R1), RTKN2 shRNA seq 2 
(R2), RTKN2 shRNA seq 3 (R3), RTKN2 shRNA seq 
4 (R4), and the ‘no DNA’ control (NN). The efficiency 
of the gene knockdown by the shRNA plasmids was 
tested in human embryonic kidney (HEK 293T) cells 
that expressed low levels of endogenous RTKN2 
mRNA. At 48 h post transfection the cells were 
processed for real time PCR. Although all four RTKN2 
shRNA constructs induced GFP expression, the target 
gene expression was only silenced by R3 and R4 
(50%–60% reduction, p  0.05, data not shown). From 
these data two RTKN2 shRNA plasmids, R2 (no gene 
knockdown), and R4 (visible gene knockdown), were 
chosen for the nucleofection of CD4+ lymphocytes, as 
well as the NC and NN controls.
nucleofection of CD4+ lymphocytes
CD4+ T-cells were isolated from umbilical cord blood 
and transfected either with NN or shRNA plasmids 
(NC, R2 and R4) using nucleofection technology. 
Twenty four hours following nucleofection, 7 AAD-ve 
viability and GFP expression were assessed by flow 
cytometry. It was noted in the first experiment that 
CD4+ T-cells transfected with the plasmid DNA had 
significantly lower viability (48.6% ± 1.6% plasmid 
DNA (NC, R2 or R4) compared with 57.5% ± 1.2% 
no DNA (NN), p  0.05, n = 3). The GFP expression 
varied (from 6% to 35%) within experiments and 
between nucleofection pulses, and was found to 
inversely correlate with cell viability (Fig. 7). It was 
deduced that either DNA alone or the expression 
of GFP was having a marked effect on the cells. 
As viability was the end-point being studied, it was 
decided that when evaluating the effect of the shRNA 
it was important to select cells within each experiment 
with the same GFP expression—before comparing 
any other cellular changes. This meant that the 
average GFP expression for the cells selected for analysis 
was equal (NC, 16.2% ± 5.1%; R2, 15.7% ± 4.6%; 
R4, 16.8% ± 5.4%, n = 6) (Fig. 8A).
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Figure 5. gene analysis of the heK stable cells. results are expressed 
as mean ± seM (n = 4). Cells were seeded at equal density and cultured 
for 6 days with samples taken for rnA extraction at 0, 3 and 6 days. real 
time PCr was performed with Applied Biosystems Assays on Demand™ 
for Bax, Bim and BCL-2, and compared to the mean of two housekeeping 
genes (β-actin and gAPDh). A) Bax gene expression was significantly 
lower in RTKN2 stables at day 0 (*p = 0.01) and day 3 (*p = 0.03) with a 
main effect between cell lines (p  0.0001, gLM). B) expression of Bim 
was overall significantly lower in RTKN2 cells (p  0.013, main effect 
between cell lines, gLM). c) There was no significant difference in gene 
expression of BCL-2 between cell lines.
Cell viability and response to oxysterol
After the cells were grouped and found to have 
statistically equivalent GFP expression, the viability 
of these subsets was assessed. Although RTKN2 was 
only silenced in a percentage of cells, the R4 group 
had significantly lower viability compared with both 
NC (control shRNA) and R2 (non-silencing shRNA) 
(p = 0.01, Fig. 8B). To test oxysterol sensitivity, 
cells that had been nucleofected and cultured for 
24 h were then cultured in the presence/absence of 
25-OHC, and the viability measured following 24 h 
treatment. At this time point (48 h post-nucleofection) 
25-OHC reduced cell viability in all shRNA groups, 
but the reduction in cell viability was found to be 
significantly greater in R4 compared to NC and R2 
(p = 0.03, Fig. 8C).
gene analysis of silenced cells
To verify gene knockdown in the transfected CD4+ 
T-cells, viable GFP positive cells were fluorescent 
activated cell sorted (FACS) using a BD FACSAria™ 
cell sorter and processed for real time PCR. When 
the values were normalized to NC, the expression 
of RTKN2 in R4 was significantly lower than both 
NC and the non-silencing R2 (p  0.05, Fig. 9A). 
As the sample size was small it was not possible to 
measure protein levels. However in order to determine 
possible involvement of genes regulating apoptotic 
signaling pathways, the expression levels of Bcl2 
family members, Bax, Bim (pro-apoptotic) and Bcl2 
(anti-apoptotic) were examined in the silenced CD4+ 
sorted samples. There was a significant increase in 
the gene expression of both Bax (p = 0.008, Fig. 9B) 
and Bim (p = 0.03, Fig. 9C) genes in the RTKN2 
silenced cells, while in contrast, Bcl2 expression was 
significantly reduced in the silenced RTKN2 cells 
(R4) (p = 0.011, Fig. 8D). It was noted that Bcl2 
expression was also slightly lower in the non-silencing 
Table 1. superarray shrnA rTKn2 sequences.
shRnA shRnA insert sequence (5′–3′)
r1 gCCAggAgAAATAgATTAAgT
r2 CCTgCAAgTgAgCCATTACAT
r3 AgAggAAATTgAAgCTAAAgT
r4 gCAACCTCAgTCTACCATgAT
nC ggAATCTCATTCgATgCATAC
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Figure 6. Western blot analysis of heK rTKn2 stable cell lysates pre- and post-immunoprecipitation (iP) with rhoA and rac2. A) Pre-iP following 
transfection with either rac2 or rhoA, protein lysates were collected (48 h post-transfection) before the immunoprecipitation step (pre-iP) (Fig. 6A). 
The samples were denatured and run in reducing conditions on a 4%–20% gradient sDs PAge gel, before transfer and immunoblotting with, anti-V5 
(to detect rTKn2), anti-hA (rac2) or anti-rhoA (rhoA). Bands were detected for all the proteins. B) Post-iP proteins lysates were then collected (48 h 
post-transfection) and immunoprecipitation performed overnight with anti-V5 (for rTKn2) and A/g sepharose. The samples (Post-iP) were denatured and 
run in reducing conditions on a 4%–20% gradient SDS PAGE gel, before transfer and immunoblotting with anti-V5 (to confirm IP), anti-HA or anti-RhoA 
(Fig. 6B). no band was detected at the correct size for either rac2 or rhoA.
group (R2) (Fig. 9D). Although this did not reach 
significance, it may have been due to a very low level 
of RTKN2 knockdown (Fig. 9A).
Discussion
The original identification of RTKN2 in a cell 
model that had been induced to become resistant to 
the oxysterol, 25-OHC1,12 indicated an association 
with the process of apoptosis. In the study described 
here we have manipulated gene and protein levels 
and demonstrated a direct role of RTKN2 in cell 
survival and apoptosis. The response of the stable 
RTKN2 over expressing HEK cells to three apoptotic 
agents differed according to the mode of action of 
the inhibitory compound, and thereby suggested 
the potential pathways by which RTKN2 may act. 
RTKN2 cells were resistant to apoptotic agents 
that acted via the intrinsic mitochondrial pathways 
(oxysterol, 25-OHC, and camptothecin) but sensitive 
to the extrinsic agent, TNFα. 25-OHC is known 
to induce apoptosis through down-regulation of 
BCL-2 expression and activation of caspases,17 
while camptothecin is a topo-isomerase inhibitor 
that interferes with transcription, induces DNA 
strand breaks and inhibits DNA division.18 The 
nuclear stress caused by camptothecin then activates 
the intrinsic mitochondrial apoptotic pathway.19
The resistance to 25-OHC and camptothecin by the 
RTKN2 cells indicated that RTKN2 expression favours 
an environment in which the cell is able to withstand 
mitochondrial death signals. The combination of 
pathway inhibitors and 25-OHC then showed that 
the RTKN2 oxysterol resistance was NF-KappaB 
pathway dependent. This role of NF-KappaB was then 
confirmed by the increased steady-state activation 
of the pathway in the RTKN2 cells. NF-KappaB is 
responsible for transcription or repression of many 
genes including the mitochondrial death genes20,21 
and down regulation of pro-apoptotic genes, Bax 
and Bim, in the HEK RTKN2 cells is consistent with 
this action and pro-survival. Although there was no 
significant change in BCL-2 expression between 
the two cell lines, as Bax inhibits the initial step of 
mitochondrial outer membrane permeabilization22 
a lower expression would be adequate for inhibition 
of cell death.
In contrast to the intrinsic agents, RTKN2 was 
sensitive to the extrinsic apoptotic action of TNFα. 
Cell death from TNFα occurs after engagement of the 
death receptor with induction of Fas-associated death 
domain-dependent (FADD) caspase-8 activation. 
In addition TNFα activates the NF-kappaB 
pathway that is known to promote cell survival.23–25 
The resultant TNFα signaling is complex, and in 
resistance to intrinsic apoptosis induced by the lymphocyte signaling protein, rTKn2
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Figure 7. inverse correlation of gFP expression in transfected CD4+ cells with viability. GFP expression was estimated by flow cytometry in the cells 
transfected with shrnAs. The percentage of gFP positivity for all shrnA transfected CD4+ cells from three separate experiments were then plotted 
against cell viability. The r2 values indicated that as the gFP expression increases, the cell viability decreases. As viability was the end-point being studied 
this inverse correlation means that only cells with the same percentage gFP expression (within an experiment) were used to evaluate viability and the 
response to an oxysterol. The values selected are indicated by the drawn circles.
instances of apoptosis, the caspase pathway outweighs 
the NF-kappaB signaling pathway.26,27 Although 
the pathway inhibitor experiment showed that the 
resistance seen in the RTKN2 cells was NF-kappaB 
dependent, the mediated survival effects appeared not 
to be at a level that could counteract the apoptotic 
induction of TNFα at 48 h. However, consistent with 
NF-KappaB activation, it was observed that RTKN2 
cells were significantly resistant to TNFα at the 
earlier 24 hour time point (data not shown) but this 
difference had disappeared by 48 h.
The NF-KappaB dependent inhibition of apoptosis 
was also seen in the other family member, rhotekin over 
expressing cells. When cell death was induced by serum 
deprivation or treatment with sodium butyrate, the 
rhotekin-mediated anti-apoptotic effect appeared to act 
via RhoA and, like RTKN2, was blocked by NF-kappaB 
inhibitors.10 As rhotekin is known to bind to RhoA with 
very high affinity28 we used the HEK stable cells to 
determine whether RTKN2 also interacted with the same 
GTPase. Rac2 was chosen as another potential binding 
partner due to its high expression in lymphocytes.29,30 
In the experiments performed in this study, neither 
RhoA nor Rac2 bound to RTKN2 in levels that were 
detectable in the co-immunoprecipitated proteins. 
However as RTKN2 has only 47% identical amino 
acid homology to rhotekin in their HR-1 (Rho-binding) 
domains and 65% in the overall protein, RTKN2 may 
not interact with the same proteins as rhotekin. Indeed, 
a recent paper noted that proteins can have 88% identity 
but still exhibit contrasting functions and structure,31 
and it is possible that RTKN2 binds with more affinity 
to one of the other Rho-GTPases or GTPase family 
members. Other potential candidates include members 
of the GTPase Immune Associated Protein (GIMAP) 
family, GTPases that have been recently identified and 
play a specific role in survival, cell cycle and apoptosis 
in lymphocytes from the human, mouse and rat.32
Having shown that over-expression of RTKN2 
conferred resistance to apoptosis we then investigated 
its role in the endogenously expressing human CD4+ 
T-cells using gene knockdown. Nucleofection, an 
electroporation-based method, was used as it has 
previously been shown to be useful in cells that are 
difficult to transfect, including hematopoietic cells such 
as NK cells,33 primary mouse CD4+ cells34 and human 
CD4+ T cell cultures.35 As expected, gene knockdown 
of RTKN2 had the opposite effect to over expression 
of the protein. Although only a percentage of the 
cells were silenced there was a small but significant 
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decrease in the cell viability of the RTKN2 silenced 
CD4+ T-cells; and furthermore, this population of 
cells was more sensitive to the apoptotic effect of 
the oxysterol, 25-OHC. The gene expression of the 
anti-apoptotic member, BCL-2,36,37 and pro-apoptotic 
members, Bax and Bim was measured in the RTKN2 
silenced T-cells and their regulation correlated to the 
behaviour of the cells and the expected phenotype 
for dying cells. The ratio of anti- and pro-apoptotic 
BCL-2 family members has been shown specifically 
to regulate T-cells from apoptotic-resistant towards an 
apoptosis-sensitive state.38 As BCL-2 not only reduces 
apoptosis but has also been shown to retard cell cycle 
entry39 RTKN2 role in lymphocyte quiescence will 
be investigated in the future. The mitochondrial 
regulated pathway is essential for spontaneous 
T-cell death32,40 and as RTKN2 was able to protect 
both HEK cells and CD4+ T-cells from this type of 
apoptosis this indicates it may play an important role 
in the life cycle of a T-lymphocyte.
RTKN2 belongs to a large family of effector 
proteins with GTPase binding domains.41 They are 
critical for the downstream signaling that follows 
binding to an activated GTPase42 and in some instances 
are cell specific.41,43 Many of the GTPase proteins and 
their effectors have previously been linked to both 
suppression and promotion of apoptosis44 dependent 
on the balance of multiple factors including; cell type, 
GTPase, activating proteins (GAPs), and the specific 
effectors.41 The studies presented here demonstrate that 
the over expression of the full length RTKN2 resulted 
in gene changes that protected HEK cells or induced 
sensitivity of CD4+ T-cells to selected mitochondrial 
apoptotic stimuli. In the HEK cells the resistance to 
apoptosis was dependent on NF-KappaB signaling 
and in CD4+ cells RTKN2 was associated with direct 
regulation of genes that correlated with a pro-death 
phenotype. In conclusion we have shown that RTKN2 
plays a similar anti-apoptotic role to rhotekin but not 
through interaction with RhoA. The pathway by which 
RTKN2 protects the cell is NF-KappaB dependent and 
involves regulation of the mitochondrial genes, Bax, 
Bim and BCL-2 in the T-cells. Being that the gene is 
specifically expressed in CD4+ cells we hypothesize 
that RTKN2 is a lymphocyte GTPase effector that 
plays a role in signal control of T-cell survival/fate 
by regulation of pro-apoptotic and anti-apoptotic 
BCL-2 genes.
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Figure 8. Transfected CD4+ cells: gFP expression, cell viability and 
response to oxysterol. results are expressed as mean ± seM (n = 6 from 
3 experiments). The GFP expression of the cells was measured using flow 
cytometry (FL-1 channel) 24 h following nucleofection. Cells that had been 
transfected with shrnAs and had similar gFP expression were selected for 
further analysis (Fig. 8A). Following 24 h culture post nucleofection, CD4+ 
T cells were removed and stained with 7-AAD. Using flow cytometry the 
percentage of 7-AAD-ve cells (FL-3 channel) was used to calculate the cell 
viability. The cells treated with the shrnA shown to silence rTKn2 (r4) 
had significantly lower viability than either the control shRNA (NC) or the 
non-silencing shrnA (r2) (p = 0.01, One-way AnOVA) (Fig. 8B). Following 
24 h culture post nucleofection, CD4+ T cells were treated with/without 
25-OhC for a further 24h before being removed and stained with 7-AAD. 
Using flow cytometry the percentage of 7-AAD-ve cells (FL-3 channel) was 
used to calculate the change in cell viability from untreated to Os treated. 
The cells treated with the shrnA shown to silence rTKn2 (r4) had a 
significantly greater drop in viability than the control shRNA (NC) (n = 3, 
p = 0.03, One-way AnOVA) (Fig. 8C).
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Methods
ethics approval
Umbilical cord blood samples were donated in 
accordance with approved institutional guidelines, 
and with appropriate ethics approval.
Transfection of mammalian cells
To establish a stable cell line, HEK Flip-In™-293 (Human 
embryonic kidney cells (Invitrogen) containing a single 
stably integrated FRT (Flp Recombinase Target site, 
Invitrogen) were utilized. A pcDNA5/FRT construct 
either containing the gene of interest (pcDNA5/FRT-
His-V5-RTKN2) or control gene (pcDNA5/FRT/
V5-His/CAT) were co-transfected with pOG44™ 
expression plasmid (allowing expression of Flp 
recombinase and integration of the pcDNA5/FRT 
plasmid within the genome, Invitrogen) into the 
host-cell line (Flip-In™-293). Incorporation of the 
pcDNA5/FRT construct into the genome occurs at 
the FRT site in the Flip-In™-293 and the pcDNA5/
FRT plasmid contains the Hygromycin resistance 
gene which allows the selection of stable cell lines. 
The control construct (as recommended by the 
manufacturer) expressed the hygromycin resistant 
gene and the recombinant protein chloramphenicol 
acetyltransferase (CAT) and has previously been 
used as a valid control.45 Transfection was carried out 
according to standard protocol and media containing 
600 µg/ml of hygromycin was used to select for CAT 
or RTKN2 expressing cells. Single colonies were 
then removed using a fine tip pipette and a dissecting 
microscope, and re-seeded in separate wells of a 
24 well plate. Confluent cells were then expanded 
and maintained in frequent changes of hygromycin 
(Invitrogen, 600 µg/ml) standard HEK media (high 
glucose (4.5 mg/L D-glucose) DMEM (Invitrogen) 
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Figure . gene analysis of the silenced CD4+ cells. results are expressed as mean ± seM (n = 4). CD4+ cells were transfected with the shrnAs and cultured 
for 24 h before the viable cells were gated and fluorescent activated cell sorted (FACS) for GFP expression. To confirm gene silencing, real time PCR was 
performed with two different RTKN2 primer pairs and 2 different housekeeping genes, and normalized to the NC. The gene expression of RTKN2 was significantly 
silenced in shrnA (r4) (p = 0.044, One way AnOVA) but not in the scrambled control (nC) or the non-silencing control (r2) (Fig. 9A). To investigate expression 
of the BCL-2 family apoptotic genes, real time PCR was performed. The gene expression of pro-apoptotic genes, Bax and Bim, were significantly higher in R4 
(*, p = 0.008 and 0.03 respectively, One way ANOVA) (Figs. 9B and 9C) compared to NC and R2, while Bcl2 expression was significantly reduced (*, p = 0.011, 
One way ANOVA) (Fig. 9D). The Bcl2 expression in R2 appeared reduced compared to the NC control but it was not statistically significant  (#, p = 0.08, One way 
AnOVA, Tukey’s Pairwise Comparison) (Fig. 9D).
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with GlutamaxTM and 10% FCS). Colonies were 
selected and established; with 2 control cell lines, 
CAT#1 and CAT#2, designated CAT control cells, 
and two with the gene of interest, RTKN2#1 and 
RTKN2#2, designated RTKN2 cells.
Western blot analysis
CAT control and RTKN2 cells were lysed in MPER 
(Pierce) for 10 min and centrifuged at 12000 × g for 
10 min at 4 oC. The clarified supernatant was separated 
from the pellet and stored for protein measurement and 
analysis. A total of 20 ug of total protein was loaded in 
each lane of the 4%–20% pre-cast Tris Glycine PAGE 
gels (GE Healthcare) and transferred on to PVDF 
membrane (iBlot Dry Blotting System, Invitrogen). 
The tagged RTKN2 full length protein (comprising 
both the GTPase-binding and PH domains) and the 
control CAT protein were visualized by western blot 
analysis using mouse anti-V5 (1:5000) (Invitrogen), 
and HRP-conjugated anti-mouse IgG (1:2000) 
(Cell Signaling) and then visualised using ECL plus 
detection reagents (Amersham) as per manufacturer’s 
instructions and imaged using the UVP ChemiDoc-It 
Imaging System (DKSH). Other antibodies used to 
determine NF-KappaB activation were anti-phospho 
NF-KappaB p65 (Cell Signaling Technology, #3033) 
and anti beta-actin (Abcam, ab6276).
induction of apoptosis
For apoptotic treatments, stock solutions of 
25-hydroxy cholesterol (25-OHC), tumour necrosis 
factor alpha (TNFα), and camptothecin (all purchased 
from Sigma) were freshly prepared in DMSO (TNFα 
and camptothecin) and ethanol (25-OHC). Working 
solutions were made up in media in which the doses 
varied depending on the treatment. Apoptosis was 
induced in cells using a range of doses; 2.5 µg/ml, 
5 µg/ml, 10 µg/ml of 25-OHC, 10 µM, 20 µM, and 
30 µM of camptothecin and 10 ng/ml, 20 ng/ml, and 
30 ng/ml of TNFα, with all treatments having equal 
amounts of the DMSO or ethanol carrier. Following 
trypsinization, the duplicate cell lines for CAT control 
and RTKN2 cells were cultured in triplicate in flow 
tubes that were cultured on rollers at 37 °C. This was 
done to allow the effective measure of apoptotic 
cells without the interference of trypsin on the cell 
membrane. At 48 h samples were removed for total 
RNA extraction, and the remaining cells were used 
to assess the viability and level of apoptosis using 
Annexin V-FITC (Becton Dickson) and propidium 
iodide (PI, Molecular Probes).
Apoptosis and pathway inhibitors
For inhibitor treatments, stock solutions of curcumin, 
parthenolide and PD98059 were freshly prepared 
in DMSO. Working solutions were made up in 
media to a known inhibitory dose, with curcumin 
10 uM, parthenolide 10 uM and PD98059 7.5 uM. 
Apoptosis was induced as described above using 
5 ug/ml 25-OHC in combination with the various 
inhibitors and at 48 h aliquots of cells were removed 
to assess the viability and level of apoptosis using 
Annexin V-FITC and PI.
Measurement of apoptosis
Annexin V binds to the phosphatidyl serine of the 
cell membrane in cells undergoing apoptosis, and 
propidium iodide (PI) intercalates with the DNA so 
that in combination the dyes can discriminate dead and 
dying cells. In brief approximately 4 × 105 cells were 
diluted with PBS to wash and centrifuged at 2500 rpm. 
Cells were then washed in 1 × Annexin V Binding 
Buffer (10 mM Hepes/NaOH, pH 7.4, 140 mM NaCl, 
2.5 mM CaCl2) and stained using Annexin V FITC 
(5 µM per tube) and PI (10 µM) for 15 minutes in the 
dark. Before flow cytometry analysis (CELLQuest 
software) 400 µl of binding buffer was added to each 
sample. The percentage of apoptotic and dying cells 
(Annexin V FITC +ve and PI +ve) was determined by 
region analysis.
Total rnA isolation, Dnase treatment 
and reverse transcription
For gene expression studies total RNA was extracted 
using Trizol® (Invitrogen) reagent, and the quantity of 
the RNA was determined by UV spectrophotometry. 
Contaminating genomic DNA was removed by 
digestion with RQ1 RNase-Free DNase (Promega) 
(30 minutes, 37 °C before inactivation of enzyme 
at 99 °C), and cDNA was prepared by reverse 
transcription using random primers and the Reverse 
Transcription System (Promega) according to 
the manufacturers guidelines.
real time assays on demand
A number of pre-designed Real-Time TaqMan® Gene 
Expression Assay mixes (Applied Biosystems) were 
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purchased for semi-quantitative PCR. These included 
RTKN2, (Hs00377175), Bax (Hs00751844), Bim 
(Hs00708019), and BCL-2 (Hs00608023), and the 
expression was compared to both housekeeping 
genes, Beta-Actin and GAPDH.
Transient transfection  
and immunoprecipitation
The constructs, pcDNA3 RhoA (a gift from Dr. Wei 
Duan, Deakin University), and pcDNA3 Rac2 (UMR 
cDNA Resource Centre), expressing constitutively 
active forms of the respective GTPase proteins 
were transiently transfected into the stable RTKN2 
HEK cells. To perform the transfection, cells were 
split to a density that reached 80%–90% confluence 
after 48 hours culture. Cells were transfected using 
Lipofectamine LTX (Invitrogen) and after 48 h an 
aliquot of each cell lysate (pre-IP) was removed and 
stored (-80 °C) for confirmation of expression of 
the recombinant proteins. The remaining samples 
were pre-cleared using either anti-mouse or rabbit 
immunoglobulin (IgG). Immunoprecipitation was then 
immediately performed with mouse-anti-V5 (RTKN2 
pull-down) antibodies and precipitated using A/G 
Sepharose beads (Santa Cruz Biotechnology). The 
co-immunoprecipitated proteins were washed a number 
of times with lysis buffer and after addition of reducing 
buffer they were then heated at 99 °C to separate 
the proteins and stored at -80 °C until western blot 
analysis. The western blot was performed as described 
above using the antibodies, mouse-anti-V5 (RTKN2) 
(Invitrogen), rabbit-anti-RhoA (Cell Signaling) or 
rabbit-anti-HA (Rac2) (Zymed Laboratories).
Preparation of hematopoietic 
mononuclear cells and immuno-magnetic 
separation of CD4+ T-cells
Mononuclear cells (MNC) from umbilical cord blood 
were prepared by density gradient separation using 
Ficoll-Paque™ PLUS (GE Healthcare Amersham 
Biosciences, Uppsala, Sweden) according to the 
manufacturer’s instructions. In brief, the samples 
were diluted with an equal volume of phosphate 
buffered saline, pH 7.4 (PBS), layered on to the 
Ficoll-Paque™ PLUS and centrifuged for 25 minutes 
at 440 g. Following centrifugation, the MNC, which 
were concentrated in a ‘fuzzy’ layer at the Ficoll-
Paque™ PLUS-plasma interface, were collected into 
sterile tubes and washed twice in at least double their 
volume of PBS. To obtain lymphocytes, the MNC’s 
were allowed to adhere to the flask (3 × 107 MNC per 
25 cm2 flask) for 2 h in RPMI with 15% FCS and the 
non-adherent cells removed for CD4+ isolation.
For separation of the T-cell subset, the non-
adherent cells were labelled with CD4-microbeads 
and positively selected using immuno-magnetic 
labelling and MACS® Technology (Miltenyi Biotec 
GmbH, Germany) according to the manufacturer’s 
instructions. The viability of the cells was assessed 
using Trypan Blue staining and purity of the population 
determined by flow cytometric analysis.
shrnA plasmids
Five pre-designed short hairpin (sh) RNA plasmids 
were supplied by Superarray SureSilencing™ to 
specifically knock down the expression of RTKN2 
by RNA interference. Four of the shRNA plasmids 
(R1–R4) comprised different regions of the RTKN2 
gene sequence, while the fifth shRNA was a negative 
control (NC) consisting of a scrambled artificial sequence 
with no sequence identity to the human genome. Each 
plasmid was incorporated with the pGeneClip™ hMGFP 
gene controlled by the U1 promoter, for identification 
and potential enrichment of the transiently transfected 
cells. The expression of GFP aided in estimating 
transfection efficiencies by flow cytometry. SuperArray 
SureSilencing™ guaranteed that at least two of the 
four RTKN2 shRNA’s would knock down at least 
70% of the targeted gene (following 100% transfection 
efficiency).46 The supplied shRNA plasmids were 
received freeze-dried and reconstituted in 200 µl of Tris 
EDTA (Sigma), (pH 8.0) buffer. Chemically competent 
cells were transformed with the plasmid and high quality 
midi-preparations of plasmid DNA were then prepared.
Efficiency of RTKN2 knockdown
Equal concentrations of the shRNA plasmids were 
prepared for transfection so that the diluted DNA 
introduced into the cells was of equal volume. To test the 
efficiency of the plasmids, standard HEK 293T cells were 
transfected, cultured for 48 h (the time recommended 
by the manufacturer for visible gene knockdown) and 
GFP expression measured by flow cytometry. The 
remaining cells were lysed with Trizol, total RNA 
extracted and cDNA synthesised. The RTKN2 gene 
expression was then determined by real time PCR.
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nucleofection of CD4+ T-cells
Nucleofection technology (AMAXA Biosystems©) 
is a recent improved form of electroporation that 
utilises a proprietary piece of equipment, the 
Nucleofector. Specific kits for each cell type have 
been developed and allow even non-dividing primary 
cells such as resting T lymphocytes to be transfected. 
The karyophilic solution provided forms a complex 
with the plasmid DNA allowing transport across the 
nuclear envelope via the nuclear pores. The CD4+ 
T-cells were isolated and nucleofection was carried 
out according to manufacturers instructions. In 
summary, approximately 5–10 × 106 CD4+ T-cells 
were mixed in a certified cuvette with 100 µl/sample 
of the appropriate cell-type specific Nucleofector 
Solution and 3 µg of shRNA plasmid. The appropriate 
Nuclefector program was set for high viability 
(V-24/V-O24) and after the electric pulse, cells 
were re-suspended in 500 µl of RPMI/FCS media. 
Cells were then transferred to a culture dish with 
an extra 1.5 ml of RPMI/FCS media and incubated 
for 6 h at 37 °C, after which the cells were washed 
and re-suspended in 2 ml of RPMI/10% FCS. Cell 
viability and GFP expression were assessed at 24 h 
and 48 h using flow cytometry. In some experiments 
the cells were divided into two groups after 24 h and 
treated with the oxysterol, 25-OHC or ethanol alone 
and cultured a further 24 h.
7-AAD and gFP expression
Cells were stained with 7-AAD (a fluorescent 
vital dye that binds DNA and does not cross intact 
plasma membranes) to enable identification of the 
viable and non-viable cells. Cells were assessed 
on a FACSCalibur flow cytometer (Becton 
Dickinson) and to determine GFP expression in 
viable cells, 7-AAD-ve stained cells were gated and 
the percentage of cells that had shifted into the FL-1 
(GFP+ve) channel compared to the negative controls. 
Analysis was performed using the CellQuest Pro 
software.
sorting of gFP+ve viable CD4+ T-cells
The BD FACSAria™ (Becton Dickinson) cell sorter 
was utilized to gate the viable CD4+ T-cells following 
24 h culture and specifically sort GFP+ve cells from 
GFP-ve cells. The sorted cells were re-suspended in 
PBS and then spun down, the supernatant aspirated 
and the cells lysed in Trizol for RNA extraction and 
cDNA transcription and real time PCR for semi-
quantitative expression of RTKN2.
statistics
Data was expressed as mean ± SEM. To analyse 
statistical differences the assumption of normality 
was made for the data, and the General Linear Model 
(GLM) performed to compare between treatments 
and treatment groups. A Tukey’s multiple comparison 
testing was performed for pairwise comparisons.
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